# Ariceum Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ariceum-therapeutics

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.ariceum-therapeutics.com
- Total disclosed funding: $25M
- Latest round: Series A (Mar 31, 2023)
- Investors on record: 3

## About

Founded in 2021 and based in Berlin, Germany, Ariceum Therapeutics operates as a radiopharmaceutical company that focuses on the diagnosis and precision treatment of neuroendocrine and aggressive and difficult-to-treat specific cancers. The company was launched in 2021 following the acquisition of all rights to its flagship product from subsequent shareholder, Ipsen. Ariceum Therapeutics has operations in Germany and is active across Europe, North America, and Australia. In March 2022, the firm raised EUR 25 million in series A funding co-led by investors EQT Life Sciences and HealthCap. Ariceum as of January 2024, is led by CEO, Manfred Rüdiger.

The company offers novel medicines for systemic targeted radiotherapy (STR) to visualize and treat cancer. Ariceum developed a proprietary peptide derivative, Satoreotide, a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor that is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumors (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide is used as a theranostic for both the diagnosis and treatment of tumors expressing the SST2 receptor. The company's therapeutics pipeline includes SSO110 (NETs), SSO110 (SCLC), and SSO111 (SCLC).

## Funding rounds

- Series A, Mar 31, 2023, $25M — Andera Partners, Earlybird, Pureos Bioventures

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series A
- Earlybird (https://capitalatlas.ai/funds/earlybird) — Series A
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series A